Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.50 |
| ▸ | NPY1R | P25929 | 7/20 | 0.50 |
| ▸ | NPY2R | P49146 | 5/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.50 |
| ▸ | BACE1 | P56817 | 5/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31665991 | 0.92 | BACE1 (0.45) | NPY4RBACE1CTSDBACE2 | |
| SCHEMBL16432553 | 0.92 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL16432550 | 0.92 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL30692435 | 0.91 | TFPI (0.47) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29886924 | 0.91 | BACE1 (0.51) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29374977 | 0.91 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29887053 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29901204 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30839890 | 0.89 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29625204 | 0.89 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | NPY4R 1087/4885NPY1R 1054/4885NPY2R 1174/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | NPY4R 807/4885NPY1R 917/4885NPY2R 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.